Prevalence of SARS-CoV-2 infection in neonates born to mothers or relatives with COVID-19

Roghayeh Babaei1, Farah Bokharaei-Salim2*, Khadijeh Khanaliha3, Seyed Jalal Kiani2, Arezoo Marjani4, Saba Garshasbi5, Farzaneh Dehghani-Dehej6 and Sara Chavoshpour4

Abstract

Background: In December 2019, in Wuhan, China, coronavirus disease 2019 (COVID-19) was emerged due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It seems that children and neonates, similar to adult and elderly individuals, are at risk of SARS-CoV-2 infection. However, adequate data are not available about neonates infected with SARS-CoV-2.

Methods: This study evaluated the presence of SARS-CoV-2 infection in neonates born to mothers or relatives with COVID-19. This cross-sectional study was performed on 25,044 consecutive Iranian participants in Tehran, Iran, from January 2020 to August 2020. Viral ribonucleic acid (RNA) was extracted from 500 µl of the oropharyngeal and nasopharyngeal specimens of the participants. The genomic RNA of SARS-CoV-2 was detected by real-time polymerase chain reaction (PCR) assay.

Results: Out of all participants, 98 (0.40%) cases were neonates born to mothers or relatives with SARS-CoV-2 infection. Therefore, the current study was performed on these neonates. Out of 98 studied neonates, 6 (6.1%) cases had positive PCR results for SARS-CoV-2 infection. Moreover, among 98 studied neonates’ mothers, 25 (25.5%) cases had positive PCR results for SARS-CoV-2 infection.

Conclusion: The findings of this study demonstrated that the rate of COVID-19 in neonates born to mothers or relatives with SARS-CoV-2 infection in the Iranian population is about 6.1%.

Keywords: COVID-19, SARS-CoV-2 infection, Coronavirus, Neonates, Pregnant women, Prevalence

Background

To date, some species of coronavirus, including NL63, 229E, HKU1, and OC43, have been identified as causing disease in humans with cold symptoms [1]. Other zoonotic species belonging to the Coronaviridae family, such as Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), which have been circulating between humans and animals, have caused severe respiratory diseases [2]. In December 2019, after identifying individuals with severe pneumonia in Wuhan, China, a new species of the Coronaviridae family was discovered, which was afterward named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19) [3–5]. Different age groups are exposed to COVID-19; however, it seems that the elderly and individuals with underlying medical conditions experience a severe and life-threatening form of COVID-19. However, children

*Correspondence: bokharaei.f@iums.ac.ir; bokharaeifarah@gmail.com
2 Department of Virology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
have been shown to have fewer clinical symptoms after being infected with SARS-CoV-2 [6, 7]. In other words, the findings showed that children experience less severe effects as a result of SARS-CoV-2 infection than adults [8]. On the other hand, accurate information about the effect of SARS-CoV-2 on neonates during the first month after birth is not available.

It is noteworthy that neonates are not similarly exposed to SARS-CoV-2 as older individuals. In addition to the fact that neonates, similar to other age groups, are exposed to SARS-CoV-2 through close contact, they are also more likely to be infected with the virus through vertical transmission during pregnancy or at birth [9].

Furthermore, the immune system response to infection in neonates is immature. On the other hand, defense mechanisms are not similar as in adults. Therefore, they may be very susceptible to infectious diseases. In frequent data have demonstrated that neonates and infants are more likely to develop the severe illness than older children [10–14]. The damage caused by COVID-19 in infants and neonates is not fully understood [15]. Recent findings have shown that no intrauterine infection due to vertical transmission has been observed in pregnant women with COVID-19 [16]. Nevertheless, the vertical transmission of SARS-CoV-2 from mother to fetus is an important and controversial issue [17]. Due to severe conditions in pregnant women and high mortality rates due to SARS-CoV and MERS-CoV, SARS-CoV-2 has caused considerable concern for pregnant women and their neonates [18–21]. In addition, susceptibility to infection and consequent hypoxia has been observed in pregnant women and their neonates [22–24].

In some countries, including China, it is suggested to separate newborns from mothers infected with SARS-CoV-2 and even prevent breastfeeding [25]. However, the World Health Organization (WHO) suggests that mothers with COVID-19 start and continue breastfeeding. It is better for the mothers and their neonates to stay in a common place together. Furthermore, the WHO emphasized that it is necessary to observe hygiene precautions [26, 27]. Significantly, the process of the separation of mothers and their newborns likely leads to psychological problems in the mother-neonate relationship [28].

To date, the required information on the status of neonates infected with SARS-CoV-2 is not available. Regarding the transmission of SARS-CoV-2 from mother to neonate and the lack of sufficient information about COVID-19 in neonates, the guidelines for the management of pregnant mothers and newborns at risk of SARS-CoV-2 have significantly changed [25, 29]. The current survey assessed the presence of SARS-CoV-2 infection in neonates born to mothers or relatives with COVID-19.

### Methods and patients
#### Study populations
From January 2020 to August 2020, 25,044 consecutive Iranian were studied in this cross-sectional survey (Fig. 1). These people had referred to one of the hospitals or clinics affiliated to Iran University of Medical Sciences (IUMS), Tehran, Iran. Of those studied, 98 (0.4%) were neonates born to mothers or all those who live together in the same house and are in contact with the neonates with COVID-19, and the present study was performed on these neonates.

#### Collection of the specimens and RNA extraction
To diagnose infection with SARS-CoV-2, the nasopharyngeal and oropharyngeal specimens were taken from the participants and placed in a viral transport media (VTM) and sent the samples to a molecular diagnostic laboratory of IUMS. It is noteworthy that only oropharyngeal samples were taken from the neonates. The viral RNA was extracted from 500 μl of the nasopharyngeal and oropharyngeal specimens using a QIAamp DSP Virus (QIAGEN GmbH, Hilden, Germany) Kit, according to the manufacturer’s instructions, and the quantity and quality of the isolated RNA was determined by a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, MA, USA) instrument.

#### SARS-CoV-2 genome amplification using real time PCR
The real-time polymerase chain reaction (RT-PCR) method was used for the detection of the genomic RNA of SARS-CoV-2 in the isolated RNA using the Rotor-Gene Q (QIAGEN, Germany) instrument. In the current study a conserved region of RdRp (RNA-dependent RNA polymerase.) and E (envelope) gene of the SARS-CoV-2 were amplified, as described previously in detail [30]. For negative and positive controls, the samples of 10 healthy people and 10 individuals with SARS-CoV-2 infection were used, respectively.

#### Statistical analysis
Statistical analysis was performed by SPSS software version 20 (SPSS Inc., Chicago, IL, USA). For evaluation of the normality of the data the Kolmogorov-Smirnov test was used, and also the statistical differences between categorical variables were examined by Fisher exact test or Chi-square test, as appropriate. It is noteworthy that, a P-value less than 0.05 (P<0.05) was considered statistically significant.

#### Results
From January 2020 to August 2020, a total of 25,044 consecutive Iranian were included in this cross sectional study. Of those studied, 98 (0.4%) were neonates born...
to mothers or relatives with Covid-19, and the current research was performed on these neonates (Fig. 1). The mean age of the neonates at the time of sampling was 4.7 ± 6.9 days (a range of: 1–28 days). Of the 98 neonates, 49 (50.0%) were male. Demographic, and laboratory data for the studied neonates and their mothers are presented in Table 1.

The RNA of SARS-CoV-2 was detected in the oro-pharyngeal samples from 6 (6.1%) of the 98 studied neonates. As a result, these neonates had Covid-19 infection. It is noteworthy that in these 6 neonates with Covid-19 disease, the mother of 3 (50.0%) neonates, the mother and father of 2 (33.3%) neonates and the grandmother of one (16.7%) neonate was infected with the SARS-Co-2.

Also, the genomic-RNA of this virus was detected in the nasopharyngeal and oropharyngeal specimens from 25 (25.5%) of the 98 studied mothers (these mothers were included in the initial screening). The demographic and epidemiological characteristics of the studied neonates and mothers of this research are shown in Tables 2 and 3. All the information about Iranian newborns with COVID-19 Infection are summarized in Table 4.

Positive PCR results of SARS-CoV-2 for all participants was observed 6751 (27.0%). Out of 25,044 (100.0%) all participants, 13,409 (53.5%) were male. The mean age of the neonates’ mothers was 30.6 ± 5.3 years (a range of: 17–41 years). Out of 49 (50.0%) male, positive and negative PCR results of SARS-CoV-2 for neonates was detected 6 (12.5%) and 43 (87.5%), respectively. Out of 49 (50.0%) female, positive and negative PCR results of SARS-CoV-2 for neonates was detected 0 (0.0%) and 49 (100.0%), respectively (Table 1). Out of the 98 neonates, 81 (82.7%) were mature and 17 (17.3%) were immature. Out of 81 (82.7%) mature neonates, positive and negative PCR results of SARS-CoV-2 was detected 5 (6.2%) and 76 (82.6%), respectively. Out of 17 (17.3%) immature neonates, positive and negative PCR results of SARS-CoV-2 was detected 1 (16.7%) and 16 (17.4%), respectively (Table 2).

In this research, a significant association was observed between PCR results of SARS-CoV-2 for all participants and gender ($P=0.0036$, Chi-Square Test). No statistically significant association was found between age of neonates/days as well as age groups of neonates (days) and gender. In addition, a significant association was observed between PCR results of SARS-CoV-2 of all neonates and gender (Table 1). No statistically significant association was observed between PCR results of SARS-CoV-2 of all neonates and age of neonates/days as well as age groups of neonates (days). Also, no statistically significant association was observed between neonatal maturity and PCR results of SARS-CoV-2 of all neonates. Furthermore, a significant association was observed between mature neonates with Covid-19 disease and fever, tachycardia as well as asymptomatic neonates (none). While, No statistically significant association was found between PCR

### Table 1

| Parameters                                      | Male                   | Female                  | Total                   | P. Value       |
|------------------------------------------------|------------------------|-------------------------|-------------------------|----------------|
| Age of all participants/days or years at the time of sampling | 41.8±14.5 (1 day-91 years) | 42.9±14.9 (1 day-93 years) | 42.5±14.7 (1 day-93 years) | 0.404 Student T Test |
| PCR results of SARS-CoV-2 for all participants | Positive 3717 (27.7%)  | 3034 (26.1%)            | 6751 (27.0%)            | 0.0036* Chi-Square Test |
|                                                  | Negative 9692 (72.3%)  | 8601 (73.9%)            | 18,293 (73.0%)          |                |
|                                                  | Total 13,409 (53.5%)   | 11,635 (46.5%)          | 25,044 (100.0%)         |                |
| Age of neonates/days at the time of sampling    | 5.2±7.8 (1–28 days)    | 4.1±5.7 (1–27 days)     | 4.7±6.9 (1–28 days)     | 0.956 Mann-Whitney U Test |
| Age groups of neonates (days)                    | 1–10 43 (87.8%)        | 46 (93.9%)              | 89 (90.8%)              | 0.500 Chi-Square Test |
|                                                  | 11–28 6 (12.2%)        | 3 (6.1%)                | 9 (9.2%)                |                |
| PCR results of SARS-CoV-2 of all neonates        | Positive 6 (12.5%)     | 0 (0.0%)                | 6 (1.1%)                | 0.013* Chi-Square Test |
|                                                  | Negative 43 (87.5%)    | 49 (100.0%)             | 92 (93.9%)              |                |
| Age of mothers/years at the time of sampling    | –                      | –                       | 30.8±5.1 (17–41 years)  | –               |
| Age groups of mothers (years)                    | 15–20 –                 | –                       | 4 (1.1%)                | –               |
|                                                  | 21–25 –                 | –                       | 12 (12.2%)              |                |
|                                                  | 26–30 –                 | –                       | 32 (32.7%)              |                |
|                                                  | 31–35 –                 | –                       | 30 (30.6%)              |                |
|                                                  | 35–40 –                 | –                       | 18 (18.4%)              |                |
|                                                  | > 40 –                  | –                       | 2 (2.0%)                |                |

*Statistically significant
results of SARS-CoV-2 of all neonates and general weakness, dyspnea, confusion, dry cough and cardiovascular disease (Table 2).

Also, no statistically significant association was observed between PCR results of SARS-CoV-2 for neonates’ mothers and age of mothers/years as well as age groups of mothers (years). In addition, a significant association was observed between PCR results of SARS-CoV-2 for neonates’ mothers and fever, chills, 

Table 2  The Demographic and Epidemiological Characteristics of the Studied Neonates of this Survey

| Parameters                        | Positive | Negative | Total    | P value |
|-----------------------------------|----------|----------|----------|---------|
| No                                | 6 (6.1%) | 92 (93.9%) | 98 (100%) | –       |
| Age of neonates/days at the time of sampling | 2.8 ± 2.0 (1–5 days) | 4.8 ± 7.0 (1–28 days) | 4.7 ± 6.8 (1–28 days) | 0.274 Mann–Whitney U Test |
| Age groups of neonates (Days)     |          |          |          |         |
| 1–10                              | 6 (100.0%) | 83 (90.2%) | 89 (90.8%) | 0.633 Chi-Square Test |
| 11–28                             | 0 (0.0%)  | 9 (9.8%)  | 9 (9.8%)  |          |
| Neonatal maturity                 |          |          |          |         |
| Mature                            | 5 (83.3%) | 76 (82.6%) | 81 (82.7%) | 0.722 Chi-Square Test |
| Immature                          | 1 (16.7%) | 16 (17.4%) | 17 (17.3%) |          |
| Epidemiological characteristics of neonates |          |          |          |         |
| None                              | 2 (33.3%) | 51 (55.4%) | 53 (54.1%) | 0.409 Fisher’s exact Test |
| Fever                             | 4 (66.7%) | 11 (12.0%) | 15 (15.3%) | 0.005 Fisher’s exact Test |
| General weakness                  | 0 (0.0%)  | 4 (4.3%)  | 4 (4.1%)  | 1.000 Fisher’s exact Test |
| Dyspnea                           | 2 (33.3%) | 23 (25.0%) | 25 (25.5%) | 0.643 Fisher’s exact Test |
| Confusion                         | 0 (0.0%)  | 2 (2.2%)  | 2 (2.0%)  | 1.000 Fisher’s exact Test |
| Dry cough                         | 1 (16.7%) | 3 (3.3%)  | 4 (4.1%)  | 0.226 Fisher’s exact Test |
| Tachycardia                       | 1 (16.7%) | 0 (0.0%)  | 1 (1.0%)  | 0.061 Fisher’s exact Test |
| Cardiovascular disease            | 0 (0.0%)  | 1 (1.1%)  | 1 (1.0%)  | 1.000 Fisher’s exact Test |

* Statistically significant

Table 3 The demographic and epidemiological characteristics of the studied mothers of this survey

| Parameters                        | Positive | Negative | Total    | P value |
|-----------------------------------|----------|----------|----------|---------|
| No                                | 25 (25.5%) | 73 (74.5%) | 98 (100%) | –       |
| Age of mothers/Years at the time of sampling | 30.2 ± 5.7 (19–39) | 30.9 ± 5.1 (17–41) | 30.8 ± 5.1 (17–41) | 0.533 Student T Test |
| Age groups of mothers (Years)     |          |          |          |         |
| 15–20                             | 1 (4.0%)  | 3 (4.1%)  | 4 (4.1%)  | 0.443 Chi-Square Test |
| 21–25                             | 6 (24.0%) | 6 (24.0%) | 12 (2.2%) |          |
| 26–30                             | 6 (24.0%) | 26 (35.6%) | 32 (32.7%) |          |
| 31–35                             | 6 (24.0%) | 24 (32.8%) | 30 (30.6%) |          |
| 36–40                             | 6 (24.0%) | 12 (16.4%) | 18 (18.4%) |          |
| > 40                              | 0 (0.0%)  | 2 (2.7%)  | 2 (2.0%)  |          |
| Epidemiological characteristics of mothers |          |          |          |         |
| None                              | 8 (32.0%) | 60 (82.2%) | 68 (68.4%) | <0.001 Fisher’s exact Test |
| Fever                             | 12 (48.0%) | 9 (12.3%)  | 21 (21.4%) | <0.001 Fisher’s exact Test |
| Chills                            | 10 (40.0%) | 7 (24.0%)  | 17 (17.3%) | <0.001 Fisher’s exact Test |
| General weakness                  | 6 (24.0%) | 3 (4.1%)  | 9 (9.2%)  | <0.001 Fisher’s exact Test |
| Skeletal pain                     | 3 (12.0%) | 1 (1.4%)  | 4 (4.1%)  | 0.016 Fisher’s exact Test |
| Hypertension                      | 1 (4.0%)  | 1 (1.4%)  | 2 (2.0%)  | 0.410 Fisher’s exact Test |
| Dyspnea                           | 1 (4.0%)  | 3 (4.1%)  | 4 (4.1%)  | 0.228 Fisher’s exact Test |
| Dry cough                         | 5 (20.0%) | 5 (6.8%)  | 10 (10.2%) | <0.001 Fisher’s exact Test |
| Tachycardia                       | 0 (0.0%)  | 1 (1.4%)  | 1 (1.0%)  | 0.568 Fisher’s exact Test |
| Acute respiratory disease         | 1 (4.0%)  | 1 (1.4%)  | 2 (2.0%)  | 0.013 Fisher’s exact Test |
| Decreased sense of smell          | 6 (24.0%) | 2 (2.7%)  | 8 (8.2%)  | <0.001 Fisher’s exact Test |
| Decreased sense of taste          | 6 (24.0%) | 2 (2.7%)  | 8 (8.2%)  | <0.001 Fisher’s exact Test |

* Statistically significant
general weakness, skeletal pain, dry cough, acute respiratory disease, decreased sense of smell, decreased sense of taste as well as asymptomatic mothers (none). While, no significant association was observed between PCR results of SARS-CoV-2 for neonates’ mothers and hypertension, dyspnea and tachycardia (Table 3).

Table 4 Complete information about Iranian Newborns with COVID-19 Infection

| Neonates | Mothers |
|----------|---------|
| No. | Age/days* | Gender | Maturity | Hospitalization | Prognosis | Clinical Characteristics | Aage/years* | PCR result | Clinical manifestations |
| 8 | 5 | Male | Mature | Yes/NICU | Survived | Fever, Tachycardia | 29 | Positive | Fever, General Weakness, Skeletal pain |
| 13 | 1 | Male | Immature | Yes/NICU | Died | Dyspnea | 29 | Positive | Dyspnea, Skeletal pain, Dry cough |
| 58 | 1 | Male | Mature | Yes/NICU | Survived | Fever | 30 | Negative | Hypertension, General Weakness, Dry cough |
| 61 | 5 | Male | Mature | Yes/NICU | Survived | Fever, Dry cough | 36 | Positive | Fever, Chills, Dry cough |
| 75 | 2 | Male | Mature | Yes/NICU | Survived | Fever | 31 | Positive | Fever, Chills, Acute respiratory disease, Dry cough, Decreased sense of smell and taste |
| 94 | 1 | Male | Mature | Yes/NICU | Survived | Fever, Dry cough | 39 | Negative | Decreased sense of smell and taste |

* At the time of sampling

Fig. 1 All results about the molecular virology assessment for SARS-CoV-2 infection in all studied participants

Discussion
Several factors, such as physical contact, respiratory droplets, and spread of aerosols, lead to individual-to-individual transmission of COVID-19 [31, 32]. In this study, out of 98 neonates born to mothers or all those who live together in the same house and are in contact with the neonates with Covid-19, 6 (6.1%) cases were
confirmed with SARS-CoV-2 infection, which had a positive result for polymerase chain reaction (PCR). It is not clear whether the transmission of SARS-CoV-2 infection occurred due to the vertical transmission from mother to neonate.

In December 2019, the spread of SARS-CoV-2 infection had rapidly increased worldwide. Initially, most cases were reported in older patients. After a while, neonates were reported to be infected with SARS-CoV-2. According to the latest data, individuals with the age of <19 years accounted for 1–5% of the SARS-CoV-2 infection. Although mortality is rare in this age group, younger children are likely to develop severe illness [6, 33–35]. Children infected with the virus show milder symptoms than adults [34]. Although the COVID-19 infection has been reported in neonates, mother-to-infant perinatal and vertical transmission of SARS-CoV-2 has not been confirmed to date [3, 34, 36–40]. One of the most important consequences of viral infections occurring during pregnancy is the intrauterine transmission. TORCH pathogens, such as toxoplasmosis, rubella, herpes simplex virus (HSV), cytomegalovirus (CMV), other Infections (parvovirus B19, varicella-zoster virus [VZV], and syphilis), human immunodeficiency virus (HIV), and Hepatitis viruses, ebola virus, and zika virus, can be transmitted from mother to fetus and infect the fetus [41]. Generally, the vertical transmission of viral infection occurs through the placenta and blood. However, this route of transmission has been demonstrated not to occur among pregnant women by SARS-CoV and MERS-CoV. Nevertheless, infection with these coronaviruses can cause severe pneumonia in mothers [42]. The SARS-CoV-2 can affect newborns in several ways, including transmission through horizontal or vertical ways, through causing infection, by maternal SARS-CoV-2 infections (e.g., preterm neonates) [43]. One study demonstrated that early infection among newborns was commonly mild and uncommon [43]. According to the WHO recommendations, this manner is not recommended for the separation of mother and newborn infant because several harmful consequences arise for the relationship between mother and neonate [28, 44, 45].

This cross-sectional study was performed on the clinical and epidemiological characteristics and neonatal and maternal results in the case of neonates born to mothers or relatives with COVID-19. To date, a limited number of studies have reported COVID-19 among pregnant women infected with SARS-CoV-2 [31]. The ribonucleic acid (RNA) of SARS-CoV-2 was detected in the oropharyngeal specimens of 6 (6.1%) subjects out of the 98 studied neonates. Moreover, the genomic RNA of SARS-CoV-2 was detected in the nasopharyngeal, and oropharyngeal samples of 25 (25.5%) cases out of the 98 studied neonates’ mothers.

This study, according to clinical manifestations, demonstrated the prevalent symptoms of these mothers with positive SARS-CoV-2 infection during COVID-19, including fever (n = 12; 48.0%), chills (n = 10; 40.0%), asymptomatic (n = 8; 32.0%), general weakness (n = 6; 24.0%), decreased sense of smell (n = 6; 24.0%), decreased sense of taste (n = 6; 24.0%), and dry cough (n = 5; 20.0%), respectively. In addition, among these neonates’ mothers, there were less common symptoms, such as skeletal pain (n = 3; 12.0%), hypertension (n = 1; 4.0%), dyspnea (n = 1; 4.0%), acute respiratory disease (n = 1; 4.0%), and tachycardia (n = 0; 0.0%), respectively. Furthermore, according to demographic and epidemiological characteristics, the common symptoms of these neonates with positive SARS-CoV-2 infection included fever (n = 4; 66.6%), and dyspnea (n = 2; 33.3%), respectively. Furthermore, among these neonates, there were less common symptoms, such as asymptomatic (n = 2; 33.3%), dry cough (n = 1; 16.7%), tachycardia (n = 1; 16.7%), cardiovascular disease (n = 0; 0.0%), general weakness (n = 0; 0.0%), and confusion (n = 0; 0.0%), respectively. The present findings seem to be consistent with the findings of other studies conducted in Wuhan, China, demonstrating fever as the common symptom among these mothers with positive SARS-CoV-2 infection [31, 46].

Severe acute respiratory syndrome (SARS) and SARS-CoV-2 have been reported to be 79% similar in sequence [47]. In the SARS infection, the rate of mortality is reported to be 10% [48]. In addition, among pregnant women, the mortality rate of SARS infection was reported as 25% [20]. In some previous studies, no cases of perinatal infection and disease have been reported among neonates born to mothers with the SARS infection [20, 49]. In some studies, the mortality rate among patients with COVID-19 has been reported to be approximately 1.4% [50].

To date, different case reports have demonstrated positive SARS-CoV-2 results within 48 h among newborns. One study reported positive SARS-CoV-2 neonates (3/33) with positive SARS-CoV-2 mothers [51]. In the UK, six neonates were positive for SARS-CoV-2 infection [52]. Another study reported a SARS-CoV-2-positive preterm newborn with a mother with a severe form of COVID-19 and positive SARS-CoV-2 for amniotic fluid [53]. Positive SARS-CoV-2 for placental tissue was evaluated in a mother with symptoms of cough and fever during delivery. In addition, there was a report of a positive SARS-CoV-2 result for the neonate [9]. In Wuhan, China, out of seven pregnant women, three neonates were positive for SARS-CoV-2 infections, and the SARS-CoV-2 infection was observed in one neonate about 36 h after
birth. The clinical characteristics among these pregnant women were reported as fever (n = 6; 86%), cough (n = 1; 14%), shortness of breath (n = 1; 14%), and diarrhea (n = 1; 14%), respectively [31]. According to a previous study performed in Wuhan, China, COVID-19 occurred in one neonate 36 h after birth; on the other hand, SARS-CoV-2 tests for cord blood and placenta in this neonate were reported as negative. As a result, it seems that the SARS-CoV-2 infection is probably not caused by vertical intrauterine transmission [31].

In one study, the rate of neonates with SARS-CoV-2 infection was reported as 7.4%. Their mothers were also positive for the SARS-CoV-2 infection [54]. In China, a neonatal case with the SARS-CoV-2 infection was reported [36]. In another study, all neonatal samples for the detection of SARS-CoV-2 were negative [39]. In China, 9 mothers with the SARS-CoV-2 infection were diagnosed by the evaluation of clinical features, and 10 mothers with the SARS-CoV-2 infection were confirmed by laboratory tests. In stool, urine, gastric fluid, and throat swab samples, PCR results for SARS-CoV-2 were negative among all neonates. However, in the throat swab specimen, PCR results for SARS-CoV-2 were positive for one neonate. The test of the throat swab specimen was repeated with a false-positive result. Consequently, SARS-CoV-2 was not detected in the umbilical cord blood and amniotic fluid [46].

This study has some limitations. It seems that screening participants for a short period could not clearly show vertical transmission from mother to newborn or transmission through other routes. The study results of one population at the time of the pandemic may differ from the results of other studied populations.

Conclusion
The findings of this study demonstrated that the rate of COVID-19 among neonates born to mothers or all those who live together in the same house and are in contact with the neonates with SARS-CoV-2 infection in the Iranian population is about 6.1%. The clinical and epidemiological characteristics of these pregnant women with the SARS-CoV-2 infection during pregnancy were approximately similar to those of pregnant women without SARS-CoV-2 infection. The transmission of SARS-CoV-2 infection due to vertical transmission from mother to neonate is not well understood. Therefore, it is required to perform further studies to evaluate the epidemiological and clinical characteristics of maternal and neonatal outcomes of pregnant mothers with SARS-CoV-2 infection during pregnancy and transmission of COVID-19 through vertical transmission from pregnant mother to neonate. It should be noted that vertical infection of SARS-CoV-2 can be proven by investigating multiple specimens such as nasopharynx, cord blood, and amniotic fluid in the early time of birth.

Acknowledgements
All the authors of this research would like to thank all of the volunteers who generously contributed to the current survey.

Authors contribution
RB and FBS designed the study and were responsible for the overall research management. KK, SJK, AM and SCP organized the analysis. SG, FBS, KK, SJK, FDD and AM prepared the manuscript. All the authors contributed to the final version of the manuscript. All authors read and approved the final manuscript.

Funding
The current study was funded by Research Deputy of Iran University of Medical Sciences (IUMS), Tehran, Iran, and Grant Number 18462.

Availability of data and materials
The datasets analyzed and/or used during the present survey are available on request from the responsible author.

Declarations
Ethics approval and consent to participate
Ethical approval for the current research was obtained from the local ethics committee of Iran University of Medical Sciences (IUMS), Tehran, Iran, in accordance with Helsinki Declaration (The ethical code: IR.IUMS.FMD.REC.1399.712). All of the subjects were informed about this survey, and an informed consent was obtained from all participants and/or their legal guardian(s) before commencing the survey.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Medical Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. 2 Department of Virology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. 3 Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences (IUMS), Tehran, Iran. 4 Department of Virology, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran. 5 Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran. 6 Deputy of Health, Iran University of Medical Sciences (IUMS), Tehran, Iran.

Received: 20 August 2021   Accepted: 18 August 2022
Published online: 08 September 2022

References
1. Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502.
2. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–92.
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020.
4. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
5. Gorbalenya AE, Baker SC, Baric R, Groot R, Groote R, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the Coronavirus Study Group. 2020.
6. Chen Z-M, Fu J-F, Shu Q, Chen Y-H, Hua C-Z, Li F-B, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020;16(3):240–6.
7. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html.
8. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369.
9. Kirtman M, Diambomba Y, Pouranen SM, Malinowski AK, Vlachodimiotropoulos E, Parks WT, et al. Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection. CMAJ. 2020;192(24):E647–50.
10. Kamdar S, Hutchinson R, Laing A, Stacey F, Ansbro K, Millar MR, et al. Perinatal infection influences but does not arrest rapid immune development in preterm babies. Nat Commun. 2020;11(1):1–14.
11. Green J, Petty J, Bromley P, Walker K, Jones L. COVID 19 in babies: knowledge for neonatal care. J Neonat Nurs. 2020.
12. Knight M, Bunch K, Vouven N, Morris E, Simpson N, Gale C, et al. Characteristics of pregnant women hospitalised with confirmed SARS-CoV-2 infection in the UK: a national cohort study using the UK Obstetric Surveillance System (UKOSS). MedRxiv. 2020.
13. Dong Y, Mo X, Hu Y, Qiu X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6).
14. Gotzinger F, Santiago-Garcia B, Nogueira-Julian A, Lanaspa M, Lancell L, Carducci FIC, et al. COVID-19 in children and adolescents in Europe: a multinational multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653–61.
15. Dong Y, Mo X, Hu Y, Qiu X, Jiang F, Jiang Z, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. 2020;145(6):e20200702.
16. Chen H, Guo J, Wang C, Loo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 2020;395(10226):809–15.
17. Chan CJ, Lee AC, Baqui AH, Tan J, Black RE. Risk of early-onset neonatal infection with maternal infection or colonization: a global systematic review and meta-analysis. PLoS Med. 2013;10(8):e1001502.
18. Favre G, Pomar L, Musso D, Baud D. 2019-nCoV epidemic: what about neonates? Lancet Lond. (England). 2020;395(10224):e40.
19. Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses. 2020;12(2):194.
20. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;191(1):292–7.
21. Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome coronavirus 2 from the mother to the infant—reply. JAMA Pediatr. 2020;174(10):1008–9.
22. Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med. 2005;33(10):S390–7.
23. Gale C, Quigley MA, Plazcek A, Knight M, Ladhani S, Draper ES, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ. 2020;369.
53. Zamaniyan M, Ebadi A, Mir SA, Rahmani Z, Haghshenas M, Azizi S. Pre-term delivery in pregnant woman with critical COVID-19 pneumonia and vertical transmission. Prenatal Diagn. 2020.
54. Bartick MC, Valdés V, Giusti A, Chapin EM, Bhana NB, Hernández-Aguilar MT, et al. Maternal and infant outcomes associated with maternity practices related to COVID-19: the COVID Mothers Study. Breastfeed Med. 2021;16(3):189–99.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.